COMMUNIQUÉS West-GlobeNewswire

Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD
04/05/2026
VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dose for treatment of wet age-related macular degeneration Data featured in oral presentation at the Association for Research in [...]
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
04/05/2026
New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn., May 04, 2026 (GLOBE [...]
Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
04/05/2026
Advances Nanox’s ongoing U.S. commercialization and deployment efforts PETACH TIKVA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical [...]
HealthLynked Launches New Consumer Platform and Multi-Site Digital Ecosystem to Redefine the Front Door to Healthcare
04/05/2026
NAPLES, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a healthcare technology company focused on patient engagement, care access, and provider connectivity, today announced the [...]
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
04/05/2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44 [...]
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
04/05/2026
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient profiles and bone health [...]
Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
04/05/2026
Six-month data from adult Cohort 4 show structural and functional improvements and a favorable safety profile; early safety data from pediatric Cohort 5 are consistent with adult cohorts Enrollment underway in pivotal [...]
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
04/05/2026
Peer-reviewed publication in prominent nephrology journal reinforces clinical differentiation of Vafseo® (vadadustat) in dialysis-dependent CKD anemia CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia [...]
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
04/05/2026
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data FDA [...]
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
04/05/2026
Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech [...]
Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting
04/05/2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data [...]
Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
04/05/2026
Data presented at IWGGD 2026 Symposium show a meaningful reduction in bone marrow burden with improvements in bone density LONDON, May 04, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today released new data from the [...]
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
04/05/2026
Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna [...]
4DMT to Participate in Upcoming Investor Conferences
04/05/2026
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
04/05/2026
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric patients with [...]
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
04/05/2026
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to [...]
Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
04/05/2026
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo Improvements observed across key symptoms, including nausea, early satiety, [...]
Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
04/05/2026
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo Improvements observed across key symptoms, including nausea, early satiety, [...]
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
04/05/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]

Pages